Release Date: 02/09/19 13:11 Summary: Corporate Investor Presentation - September 2019 Price Sensitive: No Download Document 2.55MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%